Prostate and Urologic Cancers Collaborative Group Meeting

Wednesday, September 13, 2017 8:00 a.m. – 3:00 p.m.

Room: East (3rd Floor)

Chair:

Martin Sanda, M.D., Emory University

Co-chair:

Oliver (John) Semmes, Ph.D., Eastern Virginia Medical School

NCI Program Directors:

- o Jacob Kagan, Ph.D., M.S., National Cancer Institute
- o Richard Mazurchuk, Ph.D., National Cancer Institute

Agenda

Note: Each group has to provide 2 slides to the Chair for his summary presentation of GU group activities to the steering committee.

7:00 a.m. – 8:00 a.m.	Sign-in
8:00 a.m. – 12:00 p.m.	Collaborative Group Meeting Part I
8:00 a.m. – 8:10 a.m.	 <u>Welcome</u> Martin Sanda M.D., Emory University Oliver (John) Semmes, Ph.D., Eastern Virginia Medical School
8:10 a.m. – 8:20 a.m.	<u>NCI Updates</u> Jacob Kagan, Ph.D., and Richard Mazurchuk, Ph.D., National Cancer Institute
8:20 a.m. – 8:35 a.m.	<u>Report from the Advocacy Group</u> Elda Railey, Co-Founder, Research Advocacy Network

Prostate and Urologic Cancers Collaborative Group Meeting

8:35 a.m. – 12:00 p.m.	Investigators' Reports 15 minutes presentation and discussion
8:35 a.m. – 8:50 a.m.	<u>Fucosylated Glycoproteins in Androgen-</u> <u>independent Prostate Cancer</u> Hui Zhang, Ph.D., Johns Hopkins University
8:50 a.m. – 9:05 a.m.	<u>Pursuit of Liquid Biopsies in Urine</u> John Semmes, Ph.D., East Virginia Medical School
9:05 a.m. – 9:20 a.m.	<u>Detection of Prostate Cancer RNA in Urinary</u> <u>Extracellular Vesicles</u> Martin Sanda, M.D., Emory University
9:20 a.m. – 9:35 a.m.	<u>Development of Prostate Cancer Transcripts as</u> <u>Early Detection and Prognostic Biomarkers</u> Scott Tomlins, M.D., Ph.D., University of Michigan
9:35 a.m. – 9:50 a.m.	<u>Update on Our BRL Collaborative Projects</u> Dan Chan, Ph.D., Johns Hopkins University
9:50 a.m. – 10:05 a.m.	<u>CPDR-EDRN IAA: Updates on Collaborative</u> <u>Studies</u> Shiv Srivastava Ph.D., Center for Prostate Disease Research
10:05 a.m. – 10:20 a.m.	<u>Selection of Candidate Biomarkers for Aggressive</u> <u>Prostate Cancer based on Targeted Proteomics</u> Tao Liu, Ph.D., or Karin Rodland Ph.D., Pacific Northwest National Laboratory
10:20 a.m. – 10:35 a.m.	Break

Prostate and Urologic Cancers Collaborative Group Meeting

10:35 a.m. – 12:00 p.m.	Resources and New Collaborations
10:35 a.m. – 10:50 a.m.	<u>microRNA: Prostate Cancer Biology &</u> <u>Biomarkers</u> Stanley Liu M.D., Ph.D. Sunnybrook-Odette Cancer Centre
10:50 a.m. – 11:05 a.m.	<u>Canary PASS</u> Daniel Lin, M.D., University of Washington
11:05 a.m. – 11:20 a.m.	Novel MRI and Biomarkers in Active Surveillance Michael Liss M.D., Ph.D., The University of Texas Health Science Center at San Antonio
11:20 a.m. – 11:35 a.m.	<u>NIST BRL</u> Kenneth Cole, Ph.D., National Institute of Standards and Technology
11:35 a.m. – 12:00 p.m.	<u>EDRN Informatics</u> Dan Crichton, M.S., NASA Jet Propulsion Laboratory
12:00 p.m. – 1:30 p.m.	Lunch (On Your Own)
1:30 p.m. – 3:00 p.m.	Collaborative Group Meeting Part 2 GU Pre-Validation and Validation Studies
1:30 p.m. – 1:45 p.m.	Prostate MRI and Laboratory Biomarkers in the Prostate Biopsy Naive Setting - An EDRN Prevalidation Study John T Wei, M.D., University of Michigan
1:45 p.m. – 2:00 p.m.	 Expansion of the Tissue Upgrading Study (Phase <u>II)</u> Robin Leach, Ph.D., The University of Texas Health Science Center at San Antonio Martin Sanda, M.D., Emory University

Prostate and Urologic Cancers Collaborative Group Meeting

GU Pre-Validation and Validation Studies (Continued)

2:00 p.m. – 2:15 p.m.	 <u>PCA3 Longitudinal Follow-up Study</u> John T. Wei, M.D., University of Michigan Daniel W. Chan Ph.D., Johns Hopkins University
2:15 p.m3:00 p.m.	Validation Studies – Teams' Working Meetings